# Retatrutide Research: Phase 1, 2, and 3 Trial Evidence Summarized > Retatrutide Phase 2 obesity trial: -24.2% body weight at 48 weeks. Phase 2 diabetes trial: HbA1c -2.02%, weight -16.94% at 36 weeks. Phase 1b half-life ~6 days. Full trial summaries with citations. What the randomized controlled trials actually measured — weight loss, glucose, liver fat, and pharmacokinetics — cited to source. ## Before the data Retatrutide is an investigational drug, not an approved treatment. Every number on this page comes from clinical trials conducted under controlled conditions with confirmed doses, sterility, independent monitoring, and medical supervision. These are not claims about what the compound does in general — they are reports of what was measured in specific trials with specific populations. The distinction matters, particularly because a gray market exists for research-labeled retatrutide sold outside any trial context. This page organizes the trial evidence by study: Phase 1b (first-in-human pharmacokinetics), Phase 2 obesity, Phase 2 type 2 diabetes, Phase 2 liver disease, and the structural pharmacology that explains the triple-agonist mechanism. Each finding is attributed to its source study. [Retatrutide references](/references) lists every citation in full. ## Phase 1b: first-in-human pharmacokinetics The first human exposure to retatrutide was a Phase 1b multiple-ascending-dose trial in 72 adults with type 2 diabetes, conducted by Eli Lilly researchers [4]. Doses ranged from 0.5 mg once weekly to a final cohort dose of 12 mg once weekly over 12 weeks. Key pharmacokinetic finding: retatrutide has a half-life of approximately 6 days in humans, which is the pharmacological basis for once-weekly dosing. Half-life (the time for blood concentration to fall by half) determines how long the compound remains active between injections. A 6-day half-life means the compound is still largely present at the next weekly dose. Efficacy signal: the highest-dose group lost a placebo-adjusted weight reduction of −8.96 kg (90% CI −11.16 to −6.75) over 12 weeks [4]. Daily mean glucose was reduced by −2.8 mmol/L at 3 mg. Treatment-emergent adverse events occurred in 63% of participants, mostly GI in nature; the safety profile was characterized as acceptable. ## Phase 2 obesity trial: -24.2% body weight at 48 weeks The pivotal Phase 2 obesity trial enrolled 338 adults with obesity (BMI ≥30, or 27–<30 with a weight-related comorbidity) in a 48-week randomized, double-blind, placebo-controlled design [1]. Four active dose groups (1, 4, 8, and 12 mg once weekly) were studied with a slow dose-escalation schedule. Primary outcome: mean body-weight change from baseline at 48 weeks was −24.2% at 12 mg versus −2.1% with placebo [1]. Dose-response was clear across all four active arms. A 2025 review characterized this as a step-change versus the prior incretin class [6]. Safety profile: GI adverse events (nausea, diarrhea, vomiting, constipation) were the most common and were dose-related. Dose-dependent increases in heart rate were observed, peaking at approximately week 24. Discontinuation due to adverse events was 18% at the highest dose [1]. Retatrutide results from this trial represent the strongest Phase 2 evidence of any pharmacological weight-loss agent in a published randomized controlled trial as of the time of publication. Phase 3 TRIUMPH trials are ongoing and will determine whether these results replicate at larger scale with longer follow-up. ## Phase 2 type 2 diabetes trial A separate Phase 2 trial enrolled 281 adults with type 2 diabetes and studied retatrutide at doses from 0.5 mg to 12 mg once weekly with stepwise escalation, over 36 weeks, versus placebo and an active comparator [2]. Primary glucose outcome: at 12 mg, HbA1c was reduced by −2.02 percentage points at 24 weeks, versus −0.01% with placebo [2]. HbA1c (glycated hemoglobin) is the standard three-month blood-glucose marker used in diabetes trials. Weight outcome: body weight fell by −16.94% at 36 weeks versus −3.00% with placebo at 12 mg [2]. Mild-to-moderate GI adverse events affected 35% of participants; no severe hypoglycemia (dangerously low blood sugar) and no deaths were recorded. ## Phase 2 liver disease substudy: -82.4% liver fat at 24 weeks A substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease — fatty liver linked to metabolic risk factors, formerly called NAFLD) confirmed by MRI-PDFF liver fat ≥10%, with no type 2 diabetes [5]. At 12 mg at 24 weeks, relative liver-fat change was −82.4%. Eighty-six percent of participants in the 12 mg group reached a normal liver-fat fraction below 5%. The reduction was sustained at 48 weeks (−86.0% at 12 mg) [5]. This is one of the larger liver-fat effect sizes measured for any pharmacological agent in a randomized trial. MASLD is a common metabolic comorbidity in people with obesity and type 2 diabetes, and there are no approved specific pharmacological treatments for it as of 2026. ## Structural pharmacology: how the triple-agonist docking works Li et al. (2024) resolved the cryo-EM structures of retatrutide bound to GLP-1R, GIPR, and GCGR simultaneously [3]. Key finding: retatrutide engages all three class-B GPCRs (G-protein-coupled receptors — a large family of cell-surface receptors that respond to hormones and relay signals inside the cell via G proteins) simultaneously. Its relative potency compared with native hormones is approximately 8.9x at the GIP receptor, 0.3x at the glucagon receptor, and 0.4x at the GLP-1 receptor [3]. This asymmetric potency profile means retatrutide is engineered to be a particularly strong GIP agonist — stronger than native GIP itself — while keeping glucagon agonism moderate enough to avoid hyperglycemia (excess blood-sugar elevation). The higher glucagon-receptor activity compared with the dual-agonist class is the principal addition that drives the energy-expenditure component. [How does retatrutide work](/how-it-works) covers the mechanism in depth. ## Appetite, eating behavior, and neuroscience A 2025 study analyzed appetite, eating attitudes, and eating behavior during retatrutide treatment in a clinical context [8]. A 2025 qualitative study using exit interviews with 40 Phase 2 trial participants found that 31 of 36 retatrutide-treated subjects reported changes in eating behavior within the first 8 weeks: reduced hunger frequency, greater satiety, smaller portions, altered food preferences, and feeling more in control of eating [10]. A 2025 review examined how GLP-1 receptor signaling modulates craving and reward circuitry [7]. GLP-1 receptors are expressed in areas of the brain associated with reward and food-seeking behavior; activation at these sites is one proposed mechanism for the "food noise" suppression that community reports consistently describe. This is the appetite-neuro angle through which this site reads the retatrutide record: the compound acts not just on the stomach and pancreas, but on the neural circuits that determine whether and how intensely food feels worth pursuing. ## Retatrutide vs tirzepatide No head-to-head randomized trial comparing retatrutide and tirzepatide has completed and published results as of mid-2026. An active Phase 3 comparator trial is in the TRIUMPH program (NCT05929066), but outcomes have not been reported. What the existing trial data show separately: the Phase 2 obesity trial for tirzepatide (a GIP/GLP-1 dual agonist) demonstrated approximately 20% body weight loss at the highest studied dose over 72 weeks in the SURMOUNT-1 trial. The retatrutide Phase 2 obesity trial demonstrated approximately 24% at 48 weeks. These are different trials with different populations and different durations — direct comparison is not possible from the published literature alone. The mechanistic distinction is clear: retatrutide adds glucagon-receptor agonism on top of GIP/GLP-1. A 2025 mechanistic review summarizes how the added glucagon arm contributes energy-expenditure drive that the dual-agonist approach alone does not provide [9]. Whether this translates into meaningfully better outcomes at the population level in Phase 3 is the question the ongoing TRIUMPH trials are designed to answer. ## Retatrutide results: recent data (2024–2026) A 2026 mouse and hamster model study (Briand et al.) found 31% body weight reduction in diet-induced obese mice, with fat and lean mass both reduced, food preference shifting toward lower-energy options, improved HOMA-IR (a measure of insulin resistance), and reduced liver fat [13]. Lean mass was not different from baseline after 5 weeks in hamsters at lower doses, suggesting some dose and duration dependence on lean-mass effects. A 2026 review on dietary management during anti-obesity medication use noted that GI adverse events are a dominant reason for discontinuation of incretin therapy and that targeted nutritional management may reduce symptom burden [12]. A 2026 review on managing nausea and vomiting in GLP-1-based obesity therapies addressed the area postrema (a brain region without a normal blood-brain barrier that triggers nausea) and delayed gastric emptying as mechanisms [12]. A 2026 pharmacovigilance study found dysesthesia (abnormal skin sensations — burning, prickling, or tingling) as a class signal for GLP-1 receptor agonists in a large adverse-event database [17]. Is retatrutide fda approved? No. As of mid-2026, retatrutide has not been approved by the FDA or any other regulator. The compound is in Phase 3 TRIUMPH trials. Approval, if it follows, would depend on the outcome of those trials and regulatory review. --- An editorial reading of the Phase 1–3 retatrutide record — every figure walked back to its trial, with no clinic behind the reading room and nothing here prescribed or sold.